Compounded medications are not FDA approved. FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed.

503A pharmacies vs 503B outsourcing facilities

Released: · Last reviewed:

A 503A compounding pharmacy is state-licensed and compounds for individual patients pursuant to prescriptions, overseen mainly by state boards of pharmacy. A 503B outsourcing facility is FDA-registered, may compound larger batches under cGMP, and is subject to FDA inspection. Neither status makes any compounded product FDA approved — licensing and registration are facility statuses, not product approvals, and no pharmacy is ever "FDA approved" or "FDA licensed."

503A compounding pharmacy

  • Compounds for identified patients pursuant to prescriptions
  • Primary oversight: state board of pharmacy, USP standards
  • Not registered with FDA as a manufacturer
  • Products are not FDA approved

503B outsourcing facility

  • May compound larger batches, within legal limits, without patient-specific prescriptions
  • FDA registration, cGMP requirements, FDA inspections
  • Registration is a facility status, renewed annually
  • Products are still not FDA approved

Why this matters when choosing a GLP-1 program

Providers often cite "FDA-registered 503B facility" as a quality signal. The oversight difference is real — cGMP and FDA inspection are meaningful — but the phrase is routinely misread as product approval, which it is not. A 503A pathway is not inherently inferior either; it is the lawful route for patient-specific compounding. Whichever type a provider claims, verify the specific facility: confirm 503B claims against FDA's registered outsourcing-facility list and 503A licenses against the state board, using the four-step verification workflow. Our tracked-facility statuses live in the pharmacy records database.

Frequently asked questions

What is the difference between a 503A pharmacy and a 503B outsourcing facility?

A 503A pharmacy compounds a drug for a named patient's prescription under state board oversight, while a 503B outsourcing facility registers with FDA, follows federal manufacturing (CGMP) rules and can make batches without patient-specific prescriptions; neither status makes the compounded drug FDA-approved. FDA proposed on April 30, 2026 (91 FR 23431) not to place tirzepatide, semaglutide or liraglutide on the 503B bulks list; comments closed July 30, 2026, and no final decision had been published by October 15, 2026. NexLife's plan pages name 503A pharmacies only.